Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3862803 | 0.85 | MAOA (0.79) | MAOAMAP4K4CA12CA1CA2 | |
| Water SCHEMBL2444002 | 0.85 | MAOA (0.79) | MAOAMAP4K4CA12CA1CA2 | |
| SCHEMBL11973522 | 0.83 | MEN1 (0.48) | MAOACA12CA2CA9MEN1 | |
| SCHEMBL29394565 | 0.83 | MAOA (0.84) | MAOAMAP4K4CA12CA1CA2 | |
| SCHEMBL19446666 | 0.83 | MAOA (0.84) | MAOAMAP4K4CA12CA1CA2 | |
| SCHEMBL31131353 | 0.83 | MAOA (0.84) | MAOAMAP4K4CA12CA1CA2 | |
| SCHEMBL29561461 | 0.83 | MAOA (0.84) | MAOAMAP4K4CA12CA1CA2 | |
| SCHEMBL311194 | 0.83 | MAOA (0.84) | MAOAMAP4K4CA12CA1CA2 | |
| SCHEMBL251095 | 0.83 | MAOA (0.83) | MAOAMAP4K4CA12CA1CA2 | |
| SCHEMBL29403794 | 0.83 | MAOA (0.83) | MAOAMAP4K4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | claimed |
| CN-102459167-B | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-04-01 | — | — | CN | claimed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | claimed |
| US-8691805-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-08 | — | — | US | claimed |
| EP-2421825-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-01 | — | — | EP | claimed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | claimed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | claimed |
| CN-102459167-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | claimed |
| EP-2421825-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-7371747-B2 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-05-13 | — | — | US | claimed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | claimed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | claimed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | claimed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| CN-114729205-A | Coating compositions with polysiloxane-modified carbon nanoparticles | R·瓦尔弗雷迪邦佐 | 2022-07-08 | — | — | CN | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| WO-2021064188-A1 | COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-04-08 | — | — | WO | disclosed |
| CN-112521369-A | Compounds and compositions for inhibition of FASN | 福马治疗股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3790883-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Aprinoia Therapeutics Inc. (TW) | 2021-03-17 | — | — | EP | disclosed |
| EP-3781557-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781159-A1 | COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3773554-A1 | COMBINATION COMPRISING HDAC INHIBITOR AND CD137 AGONIST FOR CANCER THERAPY | 4SC AG (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-105492008-B | Compounds and compositions for inhibition of FASN | 福马治疗股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20200261418-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | 4SC AG (DE) | 2020-08-20 | — | — | US | disclosed |
| CN-111432884-A | Combination of HDAC inhibitors with immune checkpoint modulators for cancer therapy | 4SC股份公司 | 2020-07-17 | — | — | CN | disclosed |
| EP-3678740-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | 4SC AG (DE) | 2020-07-15 | — | — | EP | disclosed |
| CN-111205490-A | Method for producing polyimide film | 达迈科技股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2019214681-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019202001-A1 | COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019200238-A1 | COMBINATIONS INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A HISTONE DEACETYLASE INHIBITOR FOR TREATING CANCER | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019197682-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019185598-A1 | COMBINATION COMPRISING HDAC INHIBITOR AND CD137 AGONIST FOR CANCER THERAPY | 4SC AG (DE) | 2019-10-03 | — | — | WO | disclosed |
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-07-18 | — | — | US | disclosed |
| WO-2019048629-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | 4SC AG (DE) | 2019-03-14 | — | — | WO | disclosed |
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | disclosed |
| US-20170239242-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | UNIVERSITÉ PARIS CITÉ (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-3197450-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-08-02 | — | — | EP | disclosed |
| CN-106750292-A | A kind of polyimides for printed electronic | 杭州福斯特光伏材料股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016046130-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-31 | — | — | WO | disclosed |
| CN-102459167-B | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-04-01 | — | — | CN | disclosed |
| US-8815855-B2 | N-sulphonylpyrroles and their use as histone deacetylase inhibitors | 4SC AG (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | disclosed |
| US-8691805-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-04-08 | — | — | US | disclosed |
| EP-2421825-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-01 | — | — | EP | disclosed |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | disclosed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | disclosed |
| CN-102459167-A | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-05-16 | — | — | CN | disclosed |
| EP-2421825-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | MAIER THOMAS | 2010-03-25 | — | — | US | disclosed |
| US-7666868-B2 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | 4SC AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1861365-B1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-7547702-B2 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | NYCOMED GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-7371747-B2 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-05-13 | — | — | US | disclosed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | disclosed |
| US-20070293667-A1 | 4-Amino-quinazolines | MEDERSKI WERNER | 2007-12-20 | — | — | US | disclosed |
| EP-1861365-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | Nycomed GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | disclosed |
| EP-1446115-A4 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-02-02 | — | — | EP | disclosed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | disclosed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004030672-A1 | USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044204-A1 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| EP-1318984-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| US-6576664-B1 | 1-amido-2-hydroxy-substituted-indanes; suppressing production of tumor necrosis factor | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-10 | — | — | US | disclosed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002024667-A1 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002014261-A2 | 4-SUBSTITUTED D-GLUTAMIC ACID DERIVATIVES FOR USE AS ANTIBIOTIC | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| CN-1268117-A | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | DU PONT PHARM CO (US) | 2000-09-27 | — | — | CN | disclosed |
| US-5391556-A | Thrombin inhibitors | KARL THOMAE GMBH (DE) | 1995-02-21 | — | — | US | disclosed |
| EP-0555824-A1 | N-alpha-arylsulfonylated benzimidazolylalaninamide derivatives, medicaments based thereon and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-18 | — | — | EP | disclosed |
| US-4166059-A | ALKALI-FAST DISAZO DISULFIMIDE DYES | CROMPTON & KNOWLES CORPORATION (US) | 1979-08-28 | — | — | US | disclosed |
| US-4166059-A | ALKALI-FAST DISAZO DISULFIMIDE DYES | CROMPTON & KNOWLES CORPORATION (US) | 1979-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | LIPA, MGLL, PNLIP | MAOA 612/4885MAP4K4 4030/4885CA12 2840/4885 |
| US-20040044204-A1 | 4-amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | MAOA 2944/4885MAP4K4 3083/4885CA12 3090/4885 |
| US-20130244997-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MAOA 467/4885MAP4K4 4396/4885CA12 4272/4885 |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | MAOA 1311/4885MAP4K4 1270/4885CA12 3971/4885 |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | HDAC1, H1-3, HDAC2 | MAOA 656/4885MAP4K4 2176/4885CA12 4723/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | MAOA 4599/4885MAP4K4 3140/4885CA12 2919/4885 |
| US-20170239242-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | LIPA, MGLL, PNLIP | MAOA 612/4885MAP4K4 4030/4885CA12 2840/4885 |
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | MGLL, LIPA, PNLIP | MAOA 656/4885MAP4K4 4122/4885CA12 2658/4885 |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | CTSB, CTSK, CTSS | MAOA 744/4885MAP4K4 1176/4885CA12 1835/4885 |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | MAOA 3217/4885MAP4K4 841/4885CA12 4227/4885 |
| US-20100074862-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC3, HDAC2 | MAOA 1863/4885MAP4K4 2395/4885CA12 4417/4885 |
| US-20200261418-A1 | HDAC INHIBITOR IN COMBINATION WITH IMMUNE CHECKPOINT MODULATOR FOR CANCER THERAPY | HDAC4, HDAC5, HDAC9 | MAOA 2694/4885MAP4K4 1026/4885CA12 1203/4885 |
| US-20060019974-A1 | Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | SERPINA3, APOL1, MGAT3 | MAOA 3788/4885MAP4K4 3538/4885CA12 3184/4885 |
| US-20070293667-A1 | 4-Amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | MAOA 3207/4885MAP4K4 2598/4885CA12 2916/4885 |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MAOA 467/4885MAP4K4 4396/4885CA12 4272/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | MAOA 3831/4885MAP4K4 3230/4885CA12 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.